Clovis Oncology (NASDAQ:CLVS) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Tuesday.

Other analysts have also issued research reports about the stock. J P Morgan Chase & Co restated a “buy” rating on shares of Clovis Oncology in a research note on Friday, August 18th. Leerink Swann decreased their price objective on shares of Clovis Oncology to $107.00 and set an “outperform” rating for the company in a report on Friday, August 18th. Evercore ISI assumed coverage on shares of Clovis Oncology in a report on Wednesday, August 16th. They issued an “in-line” rating and a $73.00 price objective for the company. Morgan Stanley decreased their price objective on shares of Clovis Oncology from $89.00 to $86.00 and set an “overweight” rating for the company in a report on Thursday, November 2nd. Finally, Royal Bank Of Canada assumed coverage on shares of Clovis Oncology in a report on Thursday, September 14th. They issued a “sector perform” rating and a $81.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $86.15.

Shares of Clovis Oncology (NASDAQ CLVS) traded down $1.62 during trading hours on Tuesday, hitting $57.69. 1,165,107 shares of the company were exchanged, compared to its average volume of 1,826,285. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.19 and a quick ratio of 3.16. Clovis Oncology has a fifty-two week low of $35.38 and a fifty-two week high of $99.45.

Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.06). The company had revenue of $16.81 million during the quarter, compared to the consensus estimate of $21.12 million. Clovis Oncology had a negative return on equity of 122.06% and a negative net margin of 947.47%. During the same quarter last year, the firm posted ($1.70) EPS. equities research analysts predict that Clovis Oncology will post -7.63 earnings per share for the current year.

In other news, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $69.50, for a total transaction of $208,500.00. Following the completion of the transaction, the insider now owns 191,583 shares of the company’s stock, valued at $13,315,018.50. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders have sold 9,000 shares of company stock valued at $653,220. Corporate insiders own 12.50% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in CLVS. Bank of Montreal Can boosted its holdings in shares of Clovis Oncology by 284.9% during the second quarter. Bank of Montreal Can now owns 2,702 shares of the biopharmaceutical company’s stock valued at $253,000 after acquiring an additional 2,000 shares during the period. Aperio Group LLC boosted its holdings in shares of Clovis Oncology by 1.7% during the second quarter. Aperio Group LLC now owns 5,093 shares of the biopharmaceutical company’s stock valued at $477,000 after acquiring an additional 83 shares during the period. Sei Investments Co. boosted its holdings in shares of Clovis Oncology by 159.9% during the second quarter. Sei Investments Co. now owns 12,239 shares of the biopharmaceutical company’s stock valued at $1,146,000 after acquiring an additional 7,529 shares during the period. TD Asset Management Inc. boosted its holdings in shares of Clovis Oncology by 349.8% during the second quarter. TD Asset Management Inc. now owns 42,852 shares of the biopharmaceutical company’s stock valued at $4,012,000 after acquiring an additional 33,326 shares during the period. Finally, Pictet Asset Management Ltd. boosted its holdings in shares of Clovis Oncology by 69.0% during the second quarter. Pictet Asset Management Ltd. now owns 315,663 shares of the biopharmaceutical company’s stock valued at $16,307,000 after acquiring an additional 128,852 shares during the period.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/05/valuengine-lowers-clovis-oncology-clvs-to-sell.html.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.